In Vitro（体外）診断 - 世界市場の考察、競合情勢、市場予測（2030年）

世界のIn Vitro（体外）診断の市場規模は、2023年に710億1,000万米ドル、2030年までに936億米ドルに達し、2024年～2030年の予測期間にCAGRで4.71％の成長が見込まれます。市場は、COVID-19のようなさまざまな感染症の有病率の上昇、さまざまながんの有病率の上昇、血液疾患の症例の増加、In Vitro診断に関する製品開発活動の増加などの要因により、プラスの収益成長を記録すると推定されます。

In Vitro診断の市場力学

In Vitro診断市場の主な促進要因の1つは、COVID-19パンデミックの発生と、COVID-19の拡大を抑制するための診断検査の差し迫った必要性です。世界保健機関（WHO）が集計した最新のデータによると、2022年11月現在、COVID-19の確定症例は世界中で2億5,532万4,963件に上り、そのうち512万7,696人が死亡しています。SARS-COV-2ウイルスの高い毒性は、世界中でパニック状態を引き起こし、世界各地でさまざまな段階のロックダウンにつながっています。このため、感染者と非感染者の両方によりよい治療を提供することを目的とした、SARS-COV-2ウイルスを検出するための診断法やキットが緊急に必要となりました。技術の進歩により、多くの逆転写酵素ポリメラーゼ連鎖反応検査や迅速抗原検査が開発され、パンデミックによって生じた緊急事態に対応するための信頼性の高い新規診断キットのニーズに応えることで、予測期間のIn Vitro診断市場の成長に好影響を与えています。

COVID-19パンデミックの他に、In Vitro診断市場の成長に寄与するもう1つの要因は、肺がんなどのさまざまながんの有病率の上昇です。WHOが引用したGLOBOCAN（2020）の調査によると、2020年、肺がんは世界中で220万6,771人の新規患者が発生し、2番目に多く診断されたがんでした。さらに、肺がんはすべてのがん種の中で死亡原因の第1位であり、世界全体で179万6,144人が死亡しています。In Vitro診断は、がんの早期診断の機会を提供し、患者によりよい臨床転帰をもたらします。

製品開発における技術の進歩とがん研究におけるより深い理解は、リキッドバイオプシーの開発につながっています。この技術はIn Vitro診断の分子診断学の分科に属し、組織生検が実行不可能であることが判明したがん診断において有益であることが証明されています。さらに、リキッドバイオプシーはがん診断に役立つだけでなく、患者に対する特定の治療介入の有効性を評価するのに役立つコンパニオン診断機器にも利用されています。したがって、がんの有病率の上昇により、がんの診断と管理を向上させるIn Vitro診断機器や製品が必要とされています。したがって、肺がんの有病率の上昇、肺がんの診断と治療におけるIn Vitro診断の利点が、In Vitro診断製品に対する需要の増加に寄与し、予測期間のIn Vitro診断市場の成長を支える可能性があります。

しかし、正確な診断検査と機器の開発における課題や、製品承認に関する厳しい規制が、In Vitro診断市場の成長を抑制する可能性があります。

さらに、COVID-19パンデミックの影響により、COVID-19に特化した検査だけでなく、さまざまな自己モニタリング・検査キットや製品に対する需要が高まり、In Vitro診断市場の収益が急増しました。COVID-19ウイルスの伝染性のため、ウイルスの拡散を抑制するための戦略の考案に向けた診断法への大きなニーズが存在しました。COVID-19株の分離とゲノム配列の同定に伴い、患者や医療従事者のさまざまな要求に応えるため、複数のCOVID-19検査キットが市場に登場しました。したがって、In Vitro診断市場はCOVID-19パンデミック中にプラスの成長率を示すと予測されました。

In Vitro診断市場のセグメント分析

In Vitro診断市場の検査タイプセグメントでは、分子診断カテゴリが予測期間に大きな成長を記録する見込みです。これは、分子診断に関連する利点により、臨床現場における分子診断の人気が高まっているためです。分子診断は、臨床診断においてより感度の高い方法と考えられており、感染性病原体のより小さな力価の検出も可能であるため、感染症を従来よりも迅速に検出できる可能性があります。これは疾患の早期診断という点で非常に重要であり、それによって患者の予後を改善することができます。

当レポートでは、世界のIn Vitro診断市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 In Vitro診断市場レポートのイントロダクション

第2章 In Vitro診断市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価
• 財務ベンチマーク

第3章 規制と特許の分析

• 米国
• 欧州
• 日本
• 中国

第4章 In Vitro診断市場の主な要因の分析

• In Vitro診断市場の促進要因
  • COVID-19などの感染症の流行
  • がんの有病率の上昇
  • 血液疾患の有病率の増加
  • 製品開発における技術の進歩
• In Vitro診断市場の抑制要因と課題
  • 正確な診断検査と機器の開発における課題
  • 製品承認に関する厳しい規制
• In Vitro診断市場の機会
  • 製品設計の改良
  • 新興市場をターゲットにした製品の発売

第5章 In Vitro診断市場のポーターのファイブフォース分析

第6章 In Vitro診断市場に対するCOVID-19の影響分析

第7章 In Vitro診断市場のレイアウト

• 製品タイプ別
  • 器具
  • 試薬
  • その他
• 検査タイプ別
  • 免疫診断
  • 血液
  • 分子診断
  • 臨床化学
• 用途別
  • 腫瘍
  • 免疫
  • 感染症
  • 心臓
  • 腎臓
• エンドユーザー別
  • 病院
  • 診断研究所
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 In Vitro診断市場：世界の企業シェア分析 - 主要3～5社

第9章 In Vitro診断市場の企業と製品のプロファイル

• F. Hoffmann-La Roche Ltd
• Abbott
• FUJIFILM Corporation
• Sysmex Corporation
• Siemens Healthcare GmbH
• BD
• Seegene Inc
• Beckman Coulter, Inc (Danaher Corporation)
• QIAGEN
• bioMerieux SA
• Bio-Rad Laboratories, Inc
• Thermo Fisher Scientific Inc
• Cisのbio (PerkinEemer)
• ARKRAY, Inc
• Ortho Clinical Diagnostics
• ACON Laboratories, Inc
• Teco Diagnostics
• EKF Diagnostics
• Besurence GmbH
• Savyon Diagnostics
• HORIBA, Ltd
• Palliance AB
• Sugentech, Inc
• Cypress Diagnostics
• Salignostics
• The Menarini Group
• DxGen Corp.
• HUMAN
• Nova Medical
• Asahi Kasei Pharma Corporation
• Agilent Technologies, Inc

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

List of Tables

• Table 1 Competitive Analysis
• Table 2 COVID-19 Impact Analysis
• Table 3 In Vitro Diagnostics Market in Global (2021-2030)
• Table 4 In Vitro Diagnostics Market in Global by Product Type (2021-2030)
• Table 5 In Vitro Diagnostics Market in Global by Test Type (2021-2030)
• Table 6 In Vitro Diagnostics Market in Global by Application (2021-2030)
• Table 7 In Vitro Diagnostics Market in Global by End User (2021-2030)
• Table 8 In Vitro Diagnostics Market in Global by Geography (2021-2030)
• Table 9 In Vitro Diagnostics Market in North America (2021-2030)
• Table 10 In Vitro Diagnostics Market in North America by Product Type (2021-2030)
• Table 11 In Vitro Diagnostics Market in North America by Test Type (2021-2030)
• Table 12 In Vitro Diagnostics Market in North America by Application (2021-2030)
• Table 13 In Vitro Diagnostics Market in North America by End User (2021-2030)
• Table 14 In Vitro Diagnostics Market in North America by Country (2021-2030)
• Table 15 In Vitro Diagnostics Market in the US (2021-2030)
• Table 16 In Vitro Diagnostics Market in Canada (2021-2030)
• Table 17 In Vitro Diagnostics Market in Mexico (2021-2030)
• Table 18 In Vitro Diagnostics Market in Europe (2021-2030)
• Table 19 In Vitro Diagnostics Market in Europe by Product Type (2021-2030)
• Table 20 In Vitro Diagnostics Market in Europe by Test Type (2021-2030)
• Table 21 In Vitro Diagnostics Market in Europe by Application (2021-2030)
• Table 22 In Vitro Diagnostics Market in Europe by End User (2021-2030)
• Table 23 In Vitro Diagnostics Market in Europe by Country (2021-2030)
• Table 24 In Vitro Diagnostics Market in France (2021-2030)
• Table 25 In Vitro Diagnostics Market in Germany (2021-2030)
• Table 26 In Vitro Diagnostics Market in the United Kingdom (2021-2030)
• Table 27 In Vitro Diagnostics Market in Italy (2021-2030)
• Table 28 In Vitro Diagnostics Market in Spain (2021-2030)
• Table 29 In Vitro Diagnostics Market in Russia (2021-2030)
• Table 30 In Vitro Diagnostics Market in Rest of Europe (2021-2030)
• Table 31 In Vitro Diagnostics Market in APAC (2021-2030)
• Table 32 In Vitro Diagnostics Market in APAC by Product Type (2021-2030)
• Table 33 In Vitro Diagnostics Market in APAC by Test Type (2021-2030)
• Table 34 In Vitro Diagnostics Market in APAC by Application (2021-2030)
• Table 35 In Vitro Diagnostics Market in APAC by End User (2021-2030)
• Table 36 In Vitro Diagnostics Market in APAC by Country (2021-2030)
• Table 37 In Vitro Diagnostics Market in China (2021-2030)
• Table 38 In Vitro Diagnostics Market in Japan (2021-2030)
• Table 39 In Vitro Diagnostics Market in India (2021-2030)
• Table 40 In Vitro Diagnostics Market in Australia (2021-2030)
• Table 41 In Vitro Diagnostics Market in South Korea (2021-2030)
• Table 42 In Vitro Diagnostics Market in Rest of APAC (2021-2030)
• Table 43 In Vitro Diagnostics Market in Rest of World (2021-2030)
• Table 44 In Vitro Diagnostics Market in RoW by Product Type (2021-2030)
• Table 45 In Vitro Diagnostics Market in RoW by Test Type (2021-2030)
• Table 46 In Vitro Diagnostics Market in RoW by Application (2021-2030)
• Table 47 In Vitro Diagnostics Market in RoW by End User (2021-2030)
• Table 48 In Vitro Diagnostics Market in RoW by Region (2021-2030)
• Table 49 In Vitro Diagnostics Market in Middle East (2021-2030)
• Table 50 In Vitro Diagnostics Market in Africa (2021-2030)
• Table 51 In Vitro Diagnostics Market in South America (2021-2030)

List of Figures

• Figure 1 Competitive Analysis
• Figure 2 COVID-19 Impact Analysis
• Figure 3 In Vitro Diagnostics Market in Global (2021-2030)
• Figure 4 In Vitro Diagnostics Market in Global by Product Type (2021-2030)
• Figure 5 In Vitro Diagnostics Market in Global by Test Type (2021-2030)
• Figure 6 In Vitro Diagnostics Market in Global by Application (2021-2030)
• Figure 7 In Vitro Diagnostics Market in Global by End User (2021-2030)
• Figure 8 In Vitro Diagnostics Market in Global by Geography (2021-2030)
• Figure 9 In Vitro Diagnostics Market in North America (2021-2030)
• Figure 10 In Vitro Diagnostics Market in North America by Product Type (2021-2030)
• Figure 11 In Vitro Diagnostics Market in North America by Test Type (2021-2030)
• Figure 12 In Vitro Diagnostics Market in North America by Application (2021-2030)
• Figure 13 In Vitro Diagnostics Market in North America by End User (2021-2030)
• Figure 14 In Vitro Diagnostics Market in North America by Country (2021-2030)
• Figure 15 In Vitro Diagnostics Market in the US (2021-2030)
• Figure 16 In Vitro Diagnostics Market in Canada (2021-2030)
• Figure 17 In Vitro Diagnostics Market in Mexico (2021-2030)
• Figure 18 In Vitro Diagnostics Market in Europe (2021-2030)
• Figure 19 In Vitro Diagnostics Market in Europe by Product Type (2021-2030)
• Figure 20 In Vitro Diagnostics Market in Europe by Test Type (2021-2030)
• Figure 21 In Vitro Diagnostics Market in Europe by Application (2021-2030)
• Figure 22 In Vitro Diagnostics Market in Europe by End User (2021-2030)
• Figure 23 In Vitro Diagnostics Market in Europe by Country (2021-2030)
• Figure 24 In Vitro Diagnostics Market in France (2021-2030)
• Figure 25 In Vitro Diagnostics Market in Germany (2021-2030)
• Figure 26 In Vitro Diagnostics Market in the United Kingdom (2021-2030)
• Figure 27 In Vitro Diagnostics Market in Italy (2021-2030)
• Figure 28 In Vitro Diagnostics Market in Spain (2021-2030)
• Figure 29 In Vitro Diagnostics Market in Russia (2021-2030)
• Figure 30 In Vitro Diagnostics Market in Rest of Europe (2021-2030)
• Figure 31 In Vitro Diagnostics Market in APAC (2021-2030)
• Figure 32 In Vitro Diagnostics Market in APAC by Product Type (2021-2030)
• Figure 33 In Vitro Diagnostics Market in APAC by Test Type (2021-2030)
• Figure 34 In Vitro Diagnostics Market in APAC by Application (2021-2030)
• Figure 35 In Vitro Diagnostics Market in APAC by End User (2021-2030)
• Figure 36 In Vitro Diagnostics Market in APAC by Country (2021-2030)
• Figure 37 In Vitro Diagnostics Market in China (2021-2030)
• Figure 38 In Vitro Diagnostics Market in Japan (2021-2030)
• Figure 39 In Vitro Diagnostics Market in India (2021-2030)
• Figure 40 In Vitro Diagnostics Market in Australia (2021-2030)
• Figure 41 In Vitro Diagnostics Market in South Korea (2021-2030)
• Figure 42 In Vitro Diagnostics Market in Rest of APAC (2021-2030)
• Figure 43 In Vitro Diagnostics Market in Rest of World (2021-2030)
• Figure 44 In Vitro Diagnostics Market in RoW by Product Type (2021-2030)
• Figure 45 In Vitro Diagnostics Market in RoW by Test Type (2021-2030)
• Figure 46 In Vitro Diagnostics Market in RoW by Application (2021-2030)
• Figure 47 In Vitro Diagnostics Market in RoW by End User (2021-2030)
• Figure 48 In Vitro Diagnostics Market in RoW by Region (2021-2030)
• Figure 49 In Vitro Diagnostics Market in Middle East (2021-2030)
• Figure 50 In Vitro Diagnostics Market in Africa (2021-2030)
• Figure 51 In Vitro Diagnostics Market in South America (2021-2030)
• Figure 52 Market Drivers
• Figure 53 Market Barriers
• Figure 54 Marker Opportunities
• Figure 55 PORTER'S Five Force Analysis

In-Vitro Diagnostics Market By Prodcut Type (Instruments, Reagents, And Others), By Test Type (Immunodiagnostics, Hematology, Molecular Diagnostics, Clinical Chemistry, And Others), By Application (Oncology, Immunology, Infectious Diseases, Cardiology, Nephrology, And Others) By End User (Hospitals, Diagnostic Laboratries, And Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to rising prevalence of various infectious diseases such as COVID-19 infection and cancers such as lung cancer.

Global in vitro diagnostics market was valued at USD 71.01 billion in 2023, growing at a CAGR of 4.71% during the forecast period from 2024 to 2030, in order to reach USD 93.60 billion by 2030. The in vitro diagnostics market is estimated to register positive revenue growth owing to the factors such as rising prevalence of various infectious diseases such as COVID-19, growing prevalence of various cancers, increasing cases of hematological diseases, and increasing product development activities with respect to in vitro diagnostics among others.

In Vitro Diagnostics Market Dynamics:

One of the major drivers of the in vitro diagnostics market was the onset of the COVID-19 pandemic and the urgency felt for the need of the diagnostic tests in order to contain the spread of the COVID-19 infection. As per the latest data collated by the World Health Organization (WHO), as of November 2022, there have been 255,324,963 confirmed cases of COVID-19, including 5,127,696 deaths across the globe. The high virulence associated with the SARS- COV-2 virus led to panic situation across the globe and led to various stages of lockdowns globally. This led to the exigent need for diagnostic methods and kits for the detection of the SARS-COV-2 virus with the aim to design better care for both infected and uninfected population groups. Technological advancements led to the development of numerous reverse transcriptase polymerase chain reaction tests as well as rapid antigen tests in order to serve the need for reliable novel diagnostic kits to meet the urgency created by the pandemic thereby positively impacting the in vitro diagnostics market growth during the forecast period.

Besides COVID-19 pandemic, another contributing factor responsible in the growth of the in vitro diagnostics market is the rising prevalence of various cancers such as lung cancer. As per the facts stated by the GLOBOCAN 2020 study cited by the WHO, in 2020, lung cancer was the second most diagnosed cancer type with 2,206,771 new cases across the globe. In addition to that, lung cancer was the leading cause of death among all cancer types accounting for 1,796,144 deaths globally. In vitro diagnostics provide an opportunity for early diagnosis of cancer thereby providing better clinical outcomes for patients.

Technological advancements in product development coupled with better understanding in cancer research led to the development of liquid biopsy. This technique comes under the molecular diagnostics branch of in vitro diagnostics and has proven to be beneficial in cancer diagnosis where tissue biopsy proved to be unfeasible. Moreover, besides helping in cancer diagnosis, liquid biopsy has also been used in the companion diagnostic device which helps in assessing the efficacy of a particular therapeutic intervention in a patient. Therefore, the rising prevalence of cancers have necessitated the need for in vitro diagnostic devices and products for improving cancer diagnosis and management. Hence, the rising prevalence of lung cancer as well as benefits of in vitro diagnostics in lung cancer diagnosis and treatment may contribute in the rising demand for in vitro diagnostic products, thereby supporting the growth of the in vitro diagnostics market during the forecast period.

However, challenges in the development of accurate diagnostic tests and equipment and stringent regulations regarding product approvals may hinder the IVD market growth.

Moreover, the impact of the COVID-19 pandemic resulted in the surge in revenue for the in vitro diagnostics market due to the growing demand for COVID-19-specific tests as well as various self-monitoring and testing kits and products. Owing to the contagious nature of the COVID-19 virus, there was a huge need for diagnostic methods in order to devise strategies for the containment of the viral spread. With the isolation and the identification of genomic sequence of the COVID-19 strain, several COVID-19 test kits made it to the market to cater to different requirements of patients and healthcare workers. Therefore, the market for in vitro diagnostics was expected to witness a positive growth rate during the COVID-19 pandemic.

In Vitro Diagnostics Market Segment Analysis:

In-Vitro Diagnostics Market by Product Type (Instruments, Reagents, and Others), by Test Type (Immunodiagnostics, Hematology, Molecular Diagnostics, Clinical Chemistry, and Others), by Application (Oncology, Immunology, Infectious Diseases, Cardiology, Nephrology, and Others) by End User (Hospitals, Diagnostic Laboratories, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the test type segment of the in vitro diagnostics market, the molecular diagnostics category is expected to register significant growth during the forecast period. This can be attributed to the growing popularity of molecular diagnostics in clinical settings due to advantages associated with them. Molecular diagnostics is considered as a more sensitive method in clinical diagnosis and allows for the detection of even smaller titers of infectious pathogens, thus offering the possibility of detecting infections faster than before. This is extremely important in terms of early disease diagnosis and thereby improving the prognosis for patient.

Furthermore, technological advancements have led to the development of innovative molecular diagnostic techniques such as liquid biopsy which has proven to aid in cancer diagnosis and management as they can provide comprehensive information on the molecular landscapes of different cancers such as non-small cell lung cancer and can also provide insights into approaches to overcome tumor heterogeneity and monitor tumors in real time.

Therefore, considering the advantages associated with molecular diagnostics, this product category is expected to generate significant revenue share eventually contributing the overall growth of the global in vitro diagnostics market during the forecast period.

Asia-Pacific is expected to register fastest growth the Overall In Vitro Diagnostics Market:

Among all the regions, Asia-Pacific is expected to account for the fastest growth in revenue generation in the global in vitro diagnostics market. Factors such as rising prevalence of lifestyle disorders such as diabetes, increasing prevalence of various cancers, growing geriatric population along with rising hematological diseases such as anemia are expected to aid in the growth of the Asia-Pacific in vitro diagnostics market. Furthermore, increase in disposable income and growing focus on improving healthcare infrastructure and access, are also expected to aid in the in vitro diagnostics market growth in this region.

One of the key driving factors of the APAC in vitro diagnostics market is the high prevalence of anemia in the region. As per the latest data provided the World Health Organization (2023), out of the global prevalent population of anemia in non-pregnant women (539,000), South-East Asia accounted for the highest regional anemic non-pregnant female population (age group- 15-49) with 234,000 people. The source further stated that in 2019, India and China registered approximately 758,200 and 190,400 cases of anemia in pregnant women. Anemia is widespread throughout the world and affects children and women of childbearing age. Anemia is associated with motor and cognitive development and diminished work capacity. In pregnant women, iron deficiency anemia is also associated with adverse reproductive effects such as preterm birth, low birth weight infants, and reduced iron storage in babies, which can lead to developmental disorders. IVDs are considered as an essential component in primary healthcare and is highly utilized in hematology-related tests for hemoglobin, white blood cell among others. Therefore, the rising prevalence of anemia in the region is expected to drive the demand for IVDs, which in turn would provide a conducive growth environment for the Asia-Pacific IVD market.

Moreover, the large presence of diabetic population in the APAC region is also a key factor stimulating the demand for in vitro diagnostic products in the region. This can be supported by the facts provided by the International Diabetes Federation. According to the IDF Diabetes Atlas 9th Edition, an estimated 87.6 million adults in the age group of 20-79 years were living with diabetes in the South-East Asia region in 2019. As per the data provided by the IDF, in 2019, China had the highest number of diabetics worldwide, with 116 million people with diabetes, which was followed by India (77 million people with diabetes). Furthermore, the factsheet by the WHO also states that the prevalence of diabetes has been higher in developing economies than in developed nations. In vitro diagnostics has been extremely beneficial for diabetes monitoring as the need for constant monitoring of glycemic levels has led to the development of numerous blood glucose self-monitoring products such as AccuChek and other products. Therefore, the rising prevalence of diabetes in the region is predicted to boost the APAC in vitro diagnostics market in the coming years.

In Vitro Diagnostics Market Key Players:

Some of the key market players operating in the in vitro diagnostics market includes F. Hoffmann-La Roche Ltd, Abbott, FUJIFILM Corporation, Sysmex Corporation, Siemens Healthcare GmbH, BD, Seegene Inc, Beckman Coulter, Inc ( Danaher Corporation), QIAGEN, bioMerieux SA, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc, Cisbio (PerkinEemer), ARKRAY, Inc, Ortho Clinical Diagnostics, ACON Laboratories, Inc., Teco Diagnostics, EKF Diagnostics, Besurence GmbH, Savyon Diagnostics, HORIBA, Ltd., Palliance AB, Sugentech, Inc, Cypress Diagnostics, Salignostics, The Menarini Group, DxGen Corp, HUMAN, Nova Biomedical, Asahi Kasei Pharma Corporation, Agilent Technologies, Inc and others.

Recent Developmental Activities in In Vitro Diagnostics Market:

In October 2022, Bio-Rad Laboratories, Inc launched their CFX Dx Real-Time PCR Detection systems- CFX(TM) Opus 96 Dx System and the CFX(TM) Opus 384 Dx System for In Vitro Diagnostics.

In March 2022, Agilent Technologies Inc announced the launch of the eal-time reverse transcriptase PCR (qRT-PCR) IVD reagent kit for the detection of SARS-CoV-2 RNA in the European markets after completing the registration of the product in accordance with the European Union regulations thereby receiving the CE-IVD mark.

In March 2022, Roche announced the launch of connected glucose monitoring system- the new Accu-Chek Instant system compatible with integrated Personalized Diabetes Management (iPDM).

Key Takeaways from the In Vitro Diagnostics Market Report Study

Market size analysis for current in vitro diagnostics market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the in vitro diagnostics market.

Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

Key companies dominating the global in vitro diagnostics market.

Various opportunities available for the other competitor in the in vitro diagnostics market space.

What are the top performing segments in 2023? How these segments will perform in 2030.

Which is the top-performing regions and countries in the current in vitro diagnostics market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for in vitro diagnostics market growth in the coming future?

Target Audience who can be benefited from this In Vitro Diagnostics Market Report Study

In Vitro Diagnostics products providers

Research organizations and consulting companies

In Vitro Diagnostics-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in in vitro diagnostics

Various End-users who want to know more about the in vitro diagnostics market and latest technological developments in the in vitro diagnostics market.

Frequently Asked Questions for In Vitro Diagnostics Market:

1. What is an In Vitro Diagnostic Device?

In vitro diagnostic products are classified as product such as instruments, systems, and reagents intended to be used in the diagnosis, monitoring, planning for treatment of disease or other conditions.

2. What is the Global market for In Vitro Diagnostics?

Global in vitro diagnostics market was valued at USD 71.01 billion in 2023, growing at a CAGR of 4.71% during the forecast period from 2024 to 2030, in order to reach USD 93.60 billion by 2030.

3. What are the drivers for Global In Vitro Diagnostics Market?

The in vitro diagnostics market is estimated to register positive revenue growth owing to the factors such as rising prevalence of various infectious diseases such as COVID-19, growing prevalence of various cancers, increasing cases of haematological diseases, and increasing product development activities with respect to in vitro diagnostics among others.

4. Who are the key players operating in Global In Vitro Diagnostics Market?

Some of the key market players operating in the in vitro diagnostics market includes F. Hoffmann-La Roche Ltd, Abbott, FUJIFILM Corporation, Sysmex Corporation, Siemens Healthcare GmbH, BD, Seegene Inc, Beckman Coulter, Inc ( Danaher Corporation), QIAGEN, bioMerieux SA, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc, Cisbio (PerkinEemer), ARKRAY, Inc, Ortho Clinical Diagnostics, ACON Laboratories, Inc., Teco Diagnostics, EKF Diagnostics, Besurence GmbH, Savyon Diagnostics, HORIBA, Ltd., Palliance AB, Sugentech, Inc, Cypress Diagnostics, Salignostics, The Menarini Group, DxGen Corp, HUMAN, Nova Biomedical, Asahi Kasei Pharma Corporation, Agilent Technologies, Inc and others.

5. Which region is expected to register fastest growth in In Vitro Diagnostics Market?

Among all the regions, Asia-Pacific is expected to account for the fastest growth in revenue generation in the global in vitro diagnostics market. Factors such as rising prevalence of lifestyle disorders such as diabetes, increasing prevalence of various cancers including lung cancers, growing geriatric population along with rising haematological diseases such as anemia are expected to aid in the growth of the Asia-Pacific in vitro diagnostics market. Furthermore, increase in disposable income and growing focus on improving healthcare infrastructure and access, are also expected to aid in the in vitro diagnostics market growth in this region.

Table of Contents

1.In Vitro Diagnostics Market Report Introduction

2.In Vitro Diagnostics Market Executive Summary

• 2.1 Scope of the Study
• 2.2 Market at Glance
• 2.3 Competitive Assessment
• 2.4 Financial Benchmarking

3. Regulatory and Patent Analysis

• 3.1 The United States
• 3.2 Europe
• 3.3 Japan
• 3.4 China

4. In Vitro Diagnostics Market Key Factors Analysis

• 4.1 In Vitro Diagnostics Market Drivers
  • 4.1.1 Increasing Prevalence of Infectious Diseases such as COVID-19 Infection
  • 4.1.2 Rising Prevalence of Cancers
  • 4.1.3 Growing Prevalence of Hematological Diseases
  • 4.1.4 Technological Advancements in Product Development
• 4.2 In Vitro Diagnostics Market Restraints and Challenges
  • 4.2.1 Challenges in The Development of Accurate Diagnostic Tests and Equipment
  • 4.2.2 Stringent Regulations Regarding Product Approvals
• 4.3 In Vitro Diagnostics Market Opportunities
  • 4.3.1 Improving on the Product Design
  • 4.3.2 Targeting Emerging Markets for Product Launches

5. In Vitro Diagnostics Market Porter's Five Forces Analysis

• 5.1 Bargaining Power of Suppliers
• 5.2 Bargaining Power of Consumers
• 5.3 Threat of New Entrants
• 5.4 Threat of Substitutes
• 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on In Vitro Diagnostics Market

7. In Vitro Diagnostics Market Layout

• 7.1 By Product Type
  • 7.1.1 Instruments
  • 7.1.2 Reagents
  • 7.1.3 Others
• 7.2 By Test Type
  • 7.2.1 Immunodiagnostics
  • 7.2.2 Hematology
  • 7.2.3 Molecular Diagnostics
  • 7.2.4 Clinical Chemistry
  • 7.2.5 Others
• 7.3 By Application
  • 7.3.1 Oncology
  • 7.3.2 Immunology
  • 7.3.3 Infectious Diseases
  • 7.3.4 Cardiology
  • 7.3.5 Nephrology
  • 7.3.6 Others
• 7.4 By End User
  • 7.4.1 Hospitals
  • 7.4.2 Diagnostic Laboratories
  • 7.3.3 Others
• 7.5 By Geography
  • 7.5.1 North America
    • 7.5.1.1 North America In Vitro Diagnostics Market, by Product Type
    • 7.5.1.2 North America In Vitro Diagnostics Market, by Test Type
    • 7.5.1.3 North America In Vitro Diagnostics Market, by Application
    • 7.5.1.4 North America In Vitro Diagnostics Market, by End User
    • 7.5.1.5 North America In Vitro Diagnostics Market, by Country
    • 7.5.1.3.1 United States
    • 7.5.1.3.2 Canada
    • 7.5.1.3.3 Mexico
  • 7.5.2 Europe
    • 7.5.2.1 Europe In Vitro Diagnostics Market, by Product Type
    • 7.5.2.2 Europe In Vitro Diagnostics Market, by Test Type
    • 7.5.2.3 Europe In Vitro Diagnostics Market, by Application
    • 7.5.2.4 Europe In Vitro Diagnostics Market, by End User
    • 7.5.2.5 Europe In Vitro Diagnostics Market, by Country
    • 7.5.2.3.1 France
    • 7.5.2.3.2 Germany
    • 7.5.2.3.3 United Kingdom
    • 7.5.2.3.4 Italy
    • 7.5.2.3.5 Spain
    • 7.5.2.3.6 Russia
    • 7.5.2.3.7 Rest of Europe
  • 7.5.3 Asia-Pacific
    • 7.5.3.1 Asia-Pacific In Vitro Diagnostics Market, by Product Type
    • 7.5.3.2 Asia-Pacific In Vitro Diagnostics Market, by Test Type
    • 7.5.3.3 Asia-Pacific In Vitro Diagnostics Market, by Application
    • 7.5.3.4 Asia-Pacific In Vitro Diagnostics Market, by End User
    • 7.5.3.5 Asia-Pacific In Vitro Diagnostics Market, by Country
    • 7.5.3.3.1 China
    • 7.5.3.3.2 Japan
    • 7.5.3.3.3 India
    • 7.5.3.3.4 Australia
    • 7.5.3.3.5 South Korea
    • 7.5.3.3.6 Rest of Asia Pacific
  • 7.5.4 Rest of the World (RoW)
    • 7.5.4.1 RoW In Vitro Diagnostics Market, by Product Type
    • 7.5.4.2 RoW In Vitro Diagnostics Market, by Test Type
    • 7.5.4.3 RoW In Vitro Diagnostics Market, by Application
    • 7.5.4.4 RoW In Vitro Diagnostics Market, by End User
    • 7.5.4.5 RoW In Vitro Diagnostics Market, by Region
    • 7.5.4.3.1 Middle East
    • 7.5.4.3.2 Africa
    • 7.5.4.3.3 South America

8. In Vitro Diagnostics Market Global Company Share Analysis - Key 3-5 Companies

9. In Vitro Diagnostics Market Company and Product Profiles

• 9.1 F. Hoffmann-La Roche Ltd
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4 Product Listing
  • 9.1.5. Entropy
• 9.2 Abbott
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4 Product Listing
  • 9.2.5. Entropy
• 9.3 FUJIFILM Corporation
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4 Product Listing
  • 9.3.5. Entropy
• 9.4 Sysmex Corporation
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4 Product Listing
  • 9.4.5. Entropy
• 9.5 Siemens Healthcare GmbH
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4 Product Listing
  • 9.5.5. Entropy
• 9.6 BD
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4 Product Listing
  • 9.6.5. Entropy
• 9.7 Seegene Inc
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4 Product Listing
  • 9.7.5. Entropy
• 9.8 Beckman Coulter, Inc (Danaher Corporation)
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4 Product Listing
  • 9.8.5. Entropy
• 9.9 QIAGEN
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4 Product Listing
  • 9.9.5. Entropy
• 9.10 bioMerieux SA
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4 Product Listing
  • 9.10.5. Entropy
• 9.11 Bio-Rad Laboratories, Inc
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4 Product Listing
  • 9.11.5. Entropy
• 9.12 Thermo Fisher Scientific Inc
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4 Product Listing
  • 9.12.5. Entropy
• 9.13 Cisbio (PerkinEemer)
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4 Product Listing
  • 9.13.5. Entropy
• 9.14 ARKRAY, Inc
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4 Product Listing
  • 9.14.5. Entropy
• 9.15 Ortho Clinical Diagnostics
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4 Product Listing
  • 9.15.5. Entropy
• 9.16 ACON Laboratories, Inc
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4 Product Listing
  • 9.16.5. Entropy
• 9.17 Teco Diagnostics
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4 Product Listing
  • 9.17.5. Entropy
• 9.18 EKF Diagnostics
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4 Product Listing
  • 9.18.5. Entropy
• 9.19 Besurence GmbH
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4 Product Listing
  • 9.19.5. Entropy
• 9.20 Savyon Diagnostics
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4 Product Listing
  • 9.20.5. Entropy
• 9.21 HORIBA, Ltd
  • 9.21.1. Company Overview
  • 9.21.2. Company Snapshot
  • 9.21.3. Financial Overview
  • 9.21.4 Product Listing
  • 9.21.5. Entropy
• 9.22 Palliance AB
  • 9.22.1. Company Overview
  • 9.22.2. Company Snapshot
  • 9.22.3. Financial Overview
  • 9.22.4 Product Listing
  • 9.22.5. Entropy
• 9.23 Sugentech, Inc
  • 9.23.1. Company Overview
  • 9.23.2. Company Snapshot
  • 9.23.3. Financial Overview
  • 9.23.4 Product Listing
  • 9.23.5. Entropy
• 9.24 Cypress Diagnostics
  • 9.24.1. Company Overview
  • 9.24.2. Company Snapshot
  • 9.24.3. Financial Overview
  • 9.24.4 Product Listing
  • 9.24.5. Entropy
• 9.25 Salignostics
  • 9.25.1. Company Overview
  • 9.25.2. Company Snapshot
  • 9.25.3. Financial Overview
  • 9.25.4 Product Listing
  • 9.25.5. Entropy
• 9.26 The Menarini Group
  • 9.26.1. Company Overview
  • 9.26.2. Company Snapshot
  • 9.26.3. Financial Overview
  • 9.26.4 Product Listing
  • 9.26.5. Entropy
• 9.27 DxGen Corp.
  • 9.27.1. Company Overview
  • 9.27.2. Company Snapshot
  • 9.27.3. Financial Overview
  • 9.27.4 Product Listing
  • 9.27.5. Entropy
• 9.28 HUMAN
  • 9.28.1. Company Overview
  • 9.28.2. Company Snapshot
  • 9.28.3. Financial Overview
  • 9.28.4 Product Listing
  • 9.28.5. Entropy
• 9.29 Nova Medical
  • 9.29.1. Company Overview
  • 9.29.2. Company Snapshot
  • 9.29.3. Financial Overview
  • 9.29.4 Product Listing
  • 9.29.5. Entropy
• 9.30 Asahi Kasei Pharma Corporation
  • 9.30.1. Company Overview
  • 9.30.2. Company Snapshot
  • 9.30.3. Financial Overview
  • 9.30.4 Product Listing
  • 9.30.5. Entropy
• 9.31 Agilent Technologies, Inc
  • 9.31.1. Company Overview
  • 9.31.2. Company Snapshot
  • 9.31.3. Financial Overview
  • 9.31.4 Product Listing
  • 9.31.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us